PubMed

Nonhypoglycemic effects of thiazolidinediones.

Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA.

Ann Intern Med. 2001 Jan 2;134(1):61-71. Review. Erratum in: Ann Intern Med 2001 Aug 21;135(4):307. PMID: 11187421 [PubMed - indexed for MEDLINE]Related articlesFree article

Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease.

Fonseca VA.

Am J Cardiol. 2003 Aug 18;92(4A):50J-60J. Review.PMID: 12957327 [PubMed - indexed for MEDLINE]Related articles

Metabolic and additional vascular effects of thiazolidinediones.

Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ.

Drugs. 2002;62(10):1463-80. Review.PMID: 12093315 [PubMed - indexed for MEDLINE]Related articles

Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.

Diamant M, Heine RJ.

Drugs. 2003;63(13):1373-405. Review.PMID: 12825962 [PubMed - indexed for MEDLINE]Related articles

Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones.

Florkowski CM.

Am J Cardiovasc Drugs. 2002;2(1):15-21. Review.PMID: 14727995 [PubMed - indexed for MEDLINE]Related articles

Hepatotoxicity with thiazolidinediones: is it a class effect?

Scheen AJ.

Drug Saf. 2001;24(12):873-88. Review.PMID: 11735645 [PubMed - indexed for MEDLINE]Related articles

Effects of the thiazolidinediones on cardiovascular risk factors.

Gilling L, Suwattee P, DeSouza C, Asnani S, Fonseca V.

Am J Cardiovasc Drugs. 2002;2(3):149-56. Review.PMID: 14727977 [PubMed - indexed for MEDLINE]Related articles

Insulin resistance and its treatment by thiazolidinediones.

Lebovitz HE, Banerji MA.

Recent Prog Horm Res. 2001;56:265-94. Review.PMID: 11237217 [PubMed - indexed for MEDLINE]Related articlesFree article

Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD.

Diabetes Care. 2002 Mar;25(3):542-9. Erratum in: Diabetes Care 2002 May;25(5):947. PMID: 11874944 [PubMed - indexed for MEDLINE]Related articlesFree article

Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.

Lebovitz HE, Kreider M, Freed MI.

Diabetes Care. 2002 May;25(5):815-21.PMID: 11978674 [PubMed - indexed for MEDLINE]Related articlesFree article

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.PMID: 15669880 [PubMed - indexed for MEDLINE]Related articles

Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice.

Gegick CG, Altheimer MD.

Endocr Pract. 2001 May-Jun;7(3):162-9. Erratum in: Endocr Pract 2001 Jul-Aug;7(4):330. PMID: 11421562 [PubMed - indexed for MEDLINE]Related articles

Troglitazone and related compounds: therapeutic potential beyond diabetes.

Fujiwara T, Horikoshi H.

Life Sci. 2000 Oct 6;67(20):2405-16. Review.PMID: 11065164 [PubMed - indexed for MEDLINE]Related articles

[Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?]

Haberbosch W.

Herz. 2007 Feb;32(1):51-7. Review. German. PMID: 17323035 [PubMed - indexed for MEDLINE]Related articles

Cardiovascular effects of insulin sensitizers in diabetes.

Jawa A, Fonseca V.

Curr Opin Investig Drugs. 2006 Sep;7(9):806-14. Review.PMID: 17002258 [PubMed - indexed for MEDLINE]Related articles

Thiazolidinediones and liver toxicity.

Scheen AJ.

Diabetes Metab. 2001 Jun;27(3):305-13. Review.PMID: 11431595 [PubMed - indexed for MEDLINE]Related articlesFree article

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.PMID: 16882108 [PubMed - indexed for MEDLINE]Related articles

[Cardiovascular effects of the thiazolidinedione troglitazone]

Yamada K, Kuzuya H, Nakano T.

Nippon Rinsho. 2000 Feb;58(2):435-9. Review. Japanese. PMID: 10707572 [PubMed - indexed for MEDLINE]Related articles

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.

Irons BK, Greene RS, Mazzolini TA, Edwards KL, Sleeper RB.

Pharmacotherapy. 2006 Feb;26(2):168-81. Review.PMID: 16466323 [PubMed - indexed for MEDLINE]Related articles